Table 1.
Characteristics of included studies.
| Author year | Country | Cancer | Stage | No. of patients | Age |
Follow-up (months) |
Sarcopenia assessment |
Cut point (cm2/m2) |
Sarcopenia (%) |
Treatment | Outcome | Adjusted major confounders | NOS score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Methods | |||||||||||||
| Ganju et al. (20) | America | Head and neck excluding p16+ oropharynx cancer | AJCC 7th III–IVB | 246 | 60 (19–88) | 35.1 (1–83) | *L3 SMI | 41 | 43 or 53 by BMI |
Martin et al. (12) | 58 | CCRT/IC+CCRT, Surgery+ | OS PFS |
Baseline BMI, Age, Sex, Race, Site, Stage, Smoke, Treatment | 7 |
| Stone et al. (21) | America | Head and neck | AJCC I–IVB | 260 | 61.1 (±11) | ND | L3 SMI | 38.5 | 52.4 | Prado et al. (6) | 55.4 | Surgery ± RT/CRT | OS | Baseline BMI, Stage, Smoke, ALB, HPV, Treatment | 7 |
| Bril et al. (22) | Netherlands | Larynx and Hypopharynx | AJCC 6/7th 0–IV | 235 | 64.7 (±9.1) | 62.4 | *L3 SMI | 43.2 | 43.2 | Wendrich et al. (23) | 46.4 | Surgery ± pre Chemo/RT ± adjuvant treatment | OS | Baseline BMI, Sex, Smoke, Site, Treatment | 7 |
| Jung et al. (24) | Korea | Head and neck | AJCC 7th III–IV | 258 | 64 (56–73) | 53.6 (26.3–70.5) | L3 SMI | 38.5 | 52.4 | Prado et al. (6), Mourtzakis et al. (25) | 6.6 | Surgery ± RT/CCRT | OS DFS |
Baseline Age, CCI, ALB, Site, HPV-P16, Smoke, Treatment | 7 |
| †Van Rijn–Dekker et al. (26) | Netherlands | HNSCC | AJCC I–IVB | 750 | ND | ND | *L3 SMI | 30.6 | 42.4 | Lowest gender-specific quartile | 25 | Chemo/RT | OS DFS |
Baseline Age, WHO score, stage, site | 6 |
| Cho et al. (17) | Korea | Head and neck | AJCC III–IVB | 221 | 59 (18–94) | 30 (1–110) | L3 SMI | 31 | 49 | Go et al. (27), Kim et al. (28) | 48.0 | RT/ CCRT/ IC+CCRT | OS, PFS | Univariate analysis | 7 |
|
‡Fattouh et al. (29) |
America | HNSCC | AJCC 6/7th M0 | 113 | ND | ≥60 | L3 SMI | 38.5 | 52.4 | Prado et al. (30), Mokdad et al. (31) | 64.6 | Chemo/RT, Surgery+ | OS | Baseline BMI, Age, Sex, Stage, Treatment | 8 |
| Grossberg et al. (18) | ND | HNSCC | AJCC 7th M0 | 190 | 57.7 (±9.4) | 68.6 | L3 SMI | 38.5 | 52.4 | Prado et al. (6), Parsons et al. (32) | 35.3 | RT/CCRT/IC+CCRT, Surgery+ | OS, | Baseline BMI, Age, Sex, Smoke, Site, Stage, Treatment, HIV, Diabetes, Cardiovascular disease | 8 |
| Nishikawa et al. (33) | Japan | HNSCC | M0 | 85 | 66 (28–89) | 29.6 (1–40.7) | L3 SMI | 30.3 | 46.7 | Prado et al. (6) | 46.0 | RT/ CCRT/ BioRT/Surgery, NACT+ | OS | Baseline weight loss, ALB, CRP | 6 |
| Tamaki et al. (34) | Japan | SCC of oropharyngeal | AJCC II–IVC | 113 | Non-sarcopenia 57.63 (±10.25); sarcopenia 63.5 (±12.91) | 0–120 | L3 SMI | 41 | 41or 43 | Martin et al. (12) | 28.3 | CCRT/surgery ± adjuvant treatment | OS DFS |
Baseline BMI, HPV-P16, Sex, Smoke, Alcohol | 6 |
| Wendrich et al. (23) |
Dutch | HNSCC | AJCC III-IV (locally advanced) | 112 | 54.5 (±9.4) | 15–90 | *L3 SMI | 43.2 | 43.2 | Non-gender-specific optimal stratification | 54.5 | CCRT | OS | Univariate analysis | 6 |
*
L3 SMI was calculated by C3 SMI using the method from Swartz et al. (8).
†
Research as a conference meeting paper and the author provided information about sarcopenia (%).
‡
Research does not have a univariate analyzed OS data.
AJCC, American Joint Committee on Cancer; BMI, body mass index; HNSCC, head and neck squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; L3, the third lumbar vertebra; No., number; ND, no description; OS, overall survival; DFS, disease-free survival; DSS, disease-specific survival; M, metastasis; NOS, Newcastle–Ottawa Scale; PFS, progression-free survival; RT, radiation therapy; SMI, skeletal muscle index.
Bold represents the value of NOS-Score.